Literature DB >> 18397827

Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.

Po C Chen1, Vishal Patil, William Guerrant, Patience Green, Adegboyega K Oyelere.   

Abstract

Histone deacetylase (HDAC) inhibition is a recent, clinically validated therapeutic strategy for cancer treatment. Small molecule HDAC inhibitors identified so far fall in to three distinct structural motifs: the zinc-binding group (ZBG), a hydrophobic linker, and a recognition cap group. Here we report the suitability of a 1,2,3-triazole ring as a surface recognition cap group-linking moiety in suberoylanilide hydroxamic acid-like (SAHA-like) HDAC inhibitors. Using "click" chemistry (Huisgen cycloaddition reaction), several triazole-linked SAHA-like hydroxamates were synthesized. Structure-activity relationship revealed that the position of the triazole moiety as well as the identity of the cap group markedly affected the in vitro HDAC inhibition and cell growth inhibitory activities of this class of compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397827     DOI: 10.1016/j.bmc.2008.03.050

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  21 in total

Review 1.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

3.  Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Authors:  Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

4.  A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.

Authors:  Hitisha K Patel; Marton I Siklos; Hazem Abdelkarim; Emma L Mendonca; Aditya Vaidya; Pavel A Petukhov; Gregory R J Thatcher
Journal:  ChemMedChem       Date:  2013-08-16       Impact factor: 3.466

5.  Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel.

Authors:  Arren Z Washington; Subhasish Tapadar; Alex George; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2015-05-06       Impact factor: 3.641

6.  Development of a chimeric c-Src kinase and HDAC inhibitor.

Authors:  Kristin S Ko; Michael E Steffey; Kristoffer R Brandvold; Matthew B Soellner
Journal:  ACS Med Chem Lett       Date:  2013-08-08       Impact factor: 4.345

7.  The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.

Authors:  Biyin Cao; Jie Li; Jingyu Zhu; Mingyun Shen; Kunkun Han; Zubin Zhang; Yang Yu; Yali Wang; Depei Wu; Suning Chen; Aining Sun; Xiaowen Tang; Yun Zhao; Chunhua Qiao; Tingjun Hou; Xinliang Mao
Journal:  J Biol Chem       Date:  2013-10-10       Impact factor: 5.157

8.  Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.

Authors:  Idris Raji; Kabir Ahluwalia; Adegboyega K Oyelere
Journal:  Bioorg Med Chem Lett       Date:  2017-01-17       Impact factor: 2.823

9.  Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.

Authors:  Berkley E Gryder; Michelle J Akbashev; Michael K Rood; Eric D Raftery; Warren M Meyers; Paulette Dillard; Shafiq Khan; Adegboyega K Oyelere
Journal:  ACS Chem Biol       Date:  2013-09-20       Impact factor: 5.100

10.  Non-peptide macrocyclic histone deacetylase inhibitors.

Authors:  Adegboyega K Oyelere; Po C Chen; William Guerrant; Sandra C Mwakwari; Rebecca Hood; Yunzhe Zhang; Yuhong Fan
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.